dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Miguel-Huguet, Bernat |
dc.contributor.author | Pardo-Mateos, Almudena |
dc.contributor.author | Perez-Garcia, Jose Manuel |
dc.contributor.author | Llombart-Cussac, Antonio |
dc.contributor.author | Moltó Abad, Marc Miquel |
dc.contributor.author | Pérez López, Jorge |
dc.contributor.author | Sampayo-Cordero, Miguel |
dc.contributor.author | Malfettone, Andrea |
dc.date.accessioned | 2020-09-02T07:46:16Z |
dc.date.available | 2020-09-02T07:46:16Z |
dc.date.issued | 2019-10-21 |
dc.identifier.citation | Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, et al. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II): a new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019 Oct 21;14(1):230. |
dc.identifier.issn | 1750-1172 |
dc.identifier.uri | https://hdl.handle.net/11351/5203 |
dc.description | Informes de casos; Estudis clínics; Teràpia de reemplaçament enzimàtic |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Orphanet Journal of Rare Diseases;14(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Malalties rares |
dc.subject | Ressenyes sistemàtiques (Investigació mèdica) |
dc.subject.mesh | Mucopolysaccharidosis II |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Enzyme Replacement Therapy |
dc.subject.mesh | Systematic Reviews as Topic |
dc.title | Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II): a new tool for evidence-based medicine in rare diseases |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13023-019-1202-6 |
dc.subject.decs | mucopolisacaridosis II |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | tratamiento de sustitución enzimática |
dc.subject.decs | revisiones sistemáticas como asunto |
dc.relation.publishversion | https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1202-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Sampayo-Cordero M, Malfettone A] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. [Miguel-Huguet B] Colorectal Unit, Department of Surgery, Hospital de Bellvitge, Barcelona, Spain. [Pardo-Mateos A] Albiotech consultores y redacción científica S.L., Madrid, Spain. [Pérez-García J] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. IOB, Institute of Oncology, QuironSalud Group, Madrid & Barcelona, Spain. [Llombart-Cussac A] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. FISABIO - Hospital Arnau de Vilanova, Valencia, Spain. [Moltó-Abad M, Pérez López J] Unitat de Malalties Minoritàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 31639024 |
dc.identifier.wos | 000491311200004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |